Investment House LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 0.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 76,553 shares of the company’s stock after acquiring an additional 265 shares during the period. Investment House LLC’s holdings in Zoetis were worth $12,670,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sei Investments Co. lifted its holdings in Zoetis by 3.0% during the 3rd quarter. Sei Investments Co. now owns 434,758 shares of the company’s stock worth $71,757,000 after purchasing an additional 12,841 shares during the last quarter. First Allied Advisory Services Inc. raised its holdings in Zoetis by 9.9% during the 3rd quarter. First Allied Advisory Services Inc. now owns 6,178 shares of the company’s stock worth $1,022,000 after purchasing an additional 556 shares during the last quarter. Brinker Capital Investments LLC acquired a new position in Zoetis in the third quarter valued at $7,325,000. Daiwa Securities Group Inc. grew its stake in Zoetis by 6.6% during the third quarter. Daiwa Securities Group Inc. now owns 23,949 shares of the company’s stock worth $3,960,000 after purchasing an additional 1,483 shares during the period. Finally, Cetera Advisors LLC grew its position in shares of Zoetis by 29.7% during the 3rd quarter. Cetera Advisors LLC now owns 5,572 shares of the company’s stock worth $921,000 after buying an additional 1,275 shares during the period. 92.50% of the stock is owned by institutional investors.
In related news, EVP Heidi C. Chen sold 1,179 shares of Zoetis stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $161.43, for a total transaction of $190,325.97. Following the sale, the executive vice president now directly owns 17,514 shares in the company, valued at $2,827,285.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Juan Ramon Alaix sold 91,747 shares of the company’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $165.46, for a total value of $15,180,458.62. Following the completion of the sale, the director now directly owns 26,694 shares in the company, valued at $4,416,789.24. The disclosure for this sale can be found here. Insiders have sold 110,606 shares of company stock worth $18,241,735 over the last three months. Insiders own 0.17% of the company’s stock.
A number of equities analysts have issued reports on ZTS shares. BidaskClub upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Thursday, December 31st. Atlantic Securities began coverage on shares of Zoetis in a report on Monday, September 21st. They set an “overweight” rating and a $191.00 price objective on the stock. Morgan Stanley raised their price objective on shares of Zoetis from $167.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, November 13th. Barclays boosted their target price on shares of Zoetis from $175.00 to $189.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Finally, Truist raised their price target on Zoetis from $160.00 to $170.00 in a report on Thursday, November 12th. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $161.14.
Zoetis stock traded down $4.17 during mid-day trading on Wednesday, hitting $161.95. 2,589,255 shares of the company traded hands, compared to its average volume of 1,687,644. The stock has a fifty day moving average price of $162.17 and a 200-day moving average price of $158.00. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 3.47. The stock has a market cap of $76.97 billion, a price-to-earnings ratio of 48.35, a price-to-earnings-growth ratio of 4.35 and a beta of 0.71. Zoetis Inc. has a one year low of $90.14 and a one year high of $176.64.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $0.91 by $0.19. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. The firm had revenue of $1.79 billion for the quarter, compared to analyst estimates of $1.63 billion. During the same period in the prior year, the company earned $0.94 EPS. The company’s revenue was up 12.8% on a year-over-year basis. Sell-side analysts predict that Zoetis Inc. will post 3.63 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 1st. Stockholders of record on Wednesday, January 20th will be given a $0.25 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date of this dividend is Tuesday, January 19th. Zoetis’s dividend payout ratio (DPR) is currently 21.98%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: How to calculate the annual rate of depreciation
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.